Abstract: Sepsis is characterized by a systemic inflammatory response. Systemic physiologic changes can occur and lead to cellular damage and organ failure. The nuclear receptor, peroxisome proliferator-activated receptor-(PPAR ), is involved in the regulation of the inflammatory response and is altered in sepsis. Thiazolidinediones (TZDs), and the cyclopentenone prostaglandin, 15d-PGJ 2 , are specific PPAR agonists. Preclinical experimental in vitro and in vivo studies have demonstrated that pharmacological activation of PPAR provides potent anti-inflammatory effects. These agents may have effects at altering the inflammatory response in clinical sepsis.
INTRODUCTION
Sepsis is a systemic response to infection and can involve a massive systemic inflammatory response that can lead to multiple organ dysfunction and death. It is a continuum of clinical entities and includes the systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, and septic shock. There are well established definitions for the sepsis continuum established for both adult and pediatric patients [1, 2] . Although antibiotic therapy treats the underlying infection, it does not reverse the cascade of signaling events activating the innate immune system. A major pathophysiologic event is that, upon interaction with invading microorganisms, the immuno-competent or parenchymal cells of the host produce an overwhelming amount of endogenous pro-inflammatory mediators. This production is regulated at the nuclear level by a rapid activation of transcription factors.
PEROXISOME PROLIFERATOR-ACTIVATED RE-CEPTORS (PPARs)
PPARs are a large superfamily of nuclear receptors which are ligand-dependent transcription factors that influence cellular responses by altering gene expression. Although PPARs were initially described as important in triglyceride and cholesterol homeostasis these receptors are also important in regulating the inflammatory response [3] . PPARs are found in numerous tissues and immune cells such as lymphocytes, monocytes, macrophages, dendritic cells and granulocytes [4] [5] [6] [7] [8] . Three isoforms of the PPAR subfamily have been identified: PPAR , PPAR or , and PPAR [3, 9] .
PPAR is important in regulating adipocyte proliferation, glucose homeostasis, and inflammation. Upon ligand binding, PPAR forms a heterodimer with the retinoic acid receptor (RXR). The interaction with the RXR allows the recruitment of a set of cofactors. This complex binds to the PPAR response element (PPRE) in the promoter region of certain target genes to modulate transcription [10] [11] [12] . PPAR can transactivate and transrepress target genes through ligand-dependent and independent mechanisms [13] [14] [15] [16] .
MODULATION OF PPAR ACTIVITY
Inflammatory conditions affect PPAR expression and function in many tissues including lung, liver, and adipose tissue [17] [18] [19] . PPAR expression was downregulated on the endothelium of thoracic aortas and in the lung in polymicrobial sepsis in rats [18, 19] . Zhou et al. demonstrated that hepatic PPAR protein expression was downregulated in the late stages of polymicrobial sepsis but was maintained early in sepsis [20, 21] .
PPAR activity is also altered in human inflammatory conditions. For example, biopsies obtained from the colon of children with Crohn's disease demonstrated a significant reduction of PPAR mRNA expression compared to control subjects [22] . Culver et al. demonstrated that nuclear PPAR expression is decreased in alveolar macrophages in patients with the inflammatory disease sarcoidosis [23] . Similarly, patients with multiple sclerosis have a significant reduction in PPAR protein expression in peripheral blood mononuclear cells (PBMC) [24] .
One of the few studies to evaluate PPAR from patients with sepsis demonstrated an increase in PPAR expression in T lymphocytes and suggested that PPAR contributes to T cell apoptosis during sepsis, leading to sepsis-induced lymphopenia [25] . Similar findings on PPAR were demonstrated by Reddy et al in polymorphonuclear (PMN) cells from patients with sepsis. It was found that PPAR mRNA expression was significantly increased in PMNs from patients with sepsis compared to the control group. The authors suggest that PPAR may play a role in the chemotactic response of PMNs in sepsis [26] . Data from our laboratory demonstrate that PBMCs isolated from children with sepsis demonstrate a decrease in nuclear PPAR protein expression [27] . However despite this decrease, we found that PPAR activity was increased in patients with septic shock compared to control patients. The PPAR activity increase in patients with septic shock may be a result of an increase in plasma levels of the endogenous ligand 15-deoxy-12,14 -prostaglandin J 2 (15d-PGJ 2 ). Together these studies suggest that PPAR expression and activity is altered in many inflammatory conditions and in many tissues and immunologic cells.
Changes in PPAR function may also be reflected in alterations in PPAR target proteins, such as the plasma adipokines, adiponectin and resistin, which have a PPAR response element in their promoter regions [28] [29] [30] . In a recent clinical study, we have observed that plasma levels of resistin and high molecular weight adiponectin (HMWA), the form of adiponectin with metabolic properties, were increased in children with septic shock on the first day of hospitalization compared with control subjects [27] . Similar to PPAR activity levels, HMWA and resistin levels were higher in patients with higher PRISM scores. Furthermore, day one resistin levels were higher in patients who did not survive from septic shock compared to survivors from septic shock. These findings suggest that the adipokines, HMWA and resistin, may be used clinically to reflect changes in PPAR activity and may represent valid biomarkers to predict outcome in patients with sepsis.
The molecular mechanisms, which alter PPAR in sepsis remain unknown. Post-translational modifications, including phosphorylation, can regulate the function of PPAR [31] . The AF-1 domain of PPAR contains a consensus mitogenactivated protein kinase (MAPK) site and phosphorylation at serine residue 82 (or 112 for PPAR 2) leads to inhibition of PPAR transactivation [32, 33] . Furthermore, this phosphorylated-induced repression is due to conformational changes that lead to altered affinity for ligands and cofactors [32, 33] . Another potential mechanism affecting PPAR involves changes in co-activator and/or co-repressor activity. Cardiac and adipose PGC-1 expression is decreased after lipopolysaccharide (LPS) administration and this correlates with a decrease in PPAR target gene activation [34, 35] . The transcription factor FoxO1 can also directly transrepresses PPAR through direct protein-protein interactions to inhibit PPAR gene expression [36, 37] . The mechanisms responsible for the changes in PPAR in sepsis are unknown and are the focus of current investigations.
THE PPAR LIGANDS AND INFLAMMATION
The insulin-sensitizing drugs, thiazolidinediones (TZDs), and the cyclopentenone prostaglandin, 15d-PGJ 2 , are specific PPAR agonists [11, 12, 38] . Thiazolidinediones are Food and Drug Administration (FDA) approved insulin-sensitizing drugs for the treatment of type 2 diabetes mellitus. However, preclinical experimental in vitro and in vivo studies have demonstrated that pharmacological activation of PPAR provides potent anti-inflammatory effects, which may be independent from their metabolic properties. In 1998, Ricote et al. and Jiang et al. independently made the initial observation that PPAR is involved in the regulation of the inflammatory response in monocytes/macrophages and raised the possibility that synthetic PPAR ligands may be of therapeutic value in inflammatory diseases [5, 39] . TZDs include rosiglitazone, pioglitazone, troglitazone, and ciglitazone [40, 41] . There is recent controversy regarding longterm treatment of type II diabetic patients with rosiglitazone and an associated increase in cardiovascular events [42] . Thiazolidinediones remain effective at reducing inflammatory mediators in non-diabetic patients with carotid artery stenosis, metabolic syndrome, and polycystic ovary syndrome [43] [44] [45] .
The endogenous ligand, 15d-PGJ 2 , is produced from arachidonic acid via cyclo-oxygenases (COX). COX-1 is constitutively expressed but COX-2 is induced after LPS stimulation through activation of nuclear factor-B (NF-B) [46, 47] . 15d-PGJ 2 can also repress the expression of inflammatory genes in activated macrophages including tumor necrosis factor-(TNF ) and COX-2 [5] . Data from our laboratory and others demonstrate that, although 15d-PGJ 2 is a PPAR ligand, its anti-inflammatory effects on NF-B activation occurs through PPAR -dependent and independent mechanisms [48] [49] [50] [51] . One mechanism by which 15d-PGJ 2 has effects is through binding of the electrophilic carbon in the cyclopentenone ring to cellular proteins, modifying signaling pathways [52] . This mechanism may account for the direct repression of NF-B by 15d-PGJ 2 [53] . Non-steroidal anti-inflammatory drugs, which inhibit cyclooxygenase (COX)-1 and COX-2, such as ibuprofen, indomethacin, flufenamic acid and fenoprofen, also bind to PPAR and activate PPAR -dependent transcription, but at much higher concentrations compared to other PPAR ligands [54] .
Clinically, 15d-PGJ 2 production may predict PPAR activation in vivo. 15d-PGJ 2 can be measured in urine, synovial fluid and plasma [55, 56] . Urinary 15d-PGJ 2 has been detected in healthy volunteers in the range of 6 to 7 pg/mg creatinine [55] . Our experimental animal data demonstrates that plasma levels of 15d-PGJ 2 are decreased in sepsis and correlate with a similar decrease in PPAR activity [57] . In humans, 15d-PGJ 2 levels also correlate with PPAR activity. Children with resolved sepsis had elevated 15d-PGJ 2 levels compared to patients with the systemic inflammatory response syndrome (SIRS) and septic shock [27] . It is not surprising that 15d-PGJ 2 is activated during the inflammatory response from sepsis. 15d-PGJ 2 is produced from arachidonic acid via cyclo-oxygenases (COX), enzymes known to be induced after LPS stimulation [46] . Therefore, 15d-PGJ 2 levels may be increased in sepsis as a compensatory mechanism and contribute to an increase in PPAR activity.
PPAR LIGANDS AND SEPSIS
Several studies have demonstrated that activation of PPAR by specific ligands significantly improves survival in clinically relevant models of septic shock [18, 19, 58] . The beneficial effect of PPAR activation is likely to be secondary to inhibition of the production of several inflammatory mediators. Data from our laboratory demonstrate that treatment with 15d-PGJ 2 and ciglitazone improves hypotension and vascular injury and reduces neutrophil infiltration in the lung, colon and liver following polymicrobial sepsis [18] . Furthermore, this reduction in inflammation leads to significantly improved survival. PPAR ligands provide beneficial effects through modulating the NF-B and AP-1 signal transduction pathways. Additionally in a model of endotoxic shock posttreatment with 15d-PGJ 2 improved survival and reduced adhesion molecule expression and neutrophil infiltration through a reduction in NF-B activation [19] .
These potent anti-inflammatory actions of PPAR ligands have been also demonstrated during the cellular innate immune response to bacterial stimuli. For example, 15d-PGJ 2 and the thiazolidinedione troglitazone suppressed thromboxane 2 (TxB 2 ) and NO production in a dose dependent manner in rat peritoneal macrophages stimulated with heat-killed Staphylococcus aureus or Escherichia coli [59] . Ciglitazone-treated C57Bl/6 mice inoculated with Streptococcus pneumoniae had fewer bacteria, reduced proinflammatory cytokine expression in the lung, and increased survival compared with vehicle-treated mice [60] . This effect however was not secondary to an increase in alveolar macrophage phagocytosis of bacteria.
Other PPAR activators have been described. Recently, the yellow in phyto-chemical pigment of curry, curcurmin has been demonstrated to exhibit anti-inflammatory properties in a rat model of sepsis by up-regulation of PPAR expression [21] . Experimental in vitro studies in kidney proximal tubular cells have also shown that cpeptide, the 31 amino acid peptide of pro-insulin, induces a concentration-dependent transcriptional activation of PPAR [61] . Interestingly, when administered in vivo to mice subjected to endotoxic shock, c-peptide demonstrated beneficial effects in improving survival and reducing the systemic inflammatory response. This therapeutic effect was associated with activation of PPAR [62] .
CONCLUSION
The PPAR pathway is clearly altered in inflammatory conditions including sepsis. Experimental in vitro and in vivo studies demonstrate the benefits of using PPAR agonists on decreasing the inflammatory response in sepsis. These agents improve outcomes in animal studies. The effects of sepsis on the PPAR pathway in clinical sepsis demonstrate that the changes in PPAR changes may be dependent on cell type studied. Furthermore it has not yet been determined whether PPAR agonists will have an impact clinically in patients with sepsis. 
